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Abstract Diabetic nephropathy is a major complication of
diabetes mellitus and the leading cause of end-stage renal
disease. Both hyperglycemia and hypertension (systemic
and/or intraglomerular) are established causal factors for
diabetic nephropathy. Nonetheless, there is growing evi-
dence that activated innate immunity and inflammation are
also contributing factors to the pathogenesis of diabetic
nephropathy. This notion is based on increasing evidence
indicating that both cytokines-chemokines and pro-fibrotic
growth factors are important players in the progression of
diabetic nephropathy, effectively accelerating and exacer-
bating inflammatory and fibrotic processes leading to end-
stage renal disease. In this review, we focus on several
predominant cytokines-chemokines as potential predictive
markers for diabetic nephropathy. These cytokines-
chemokines may also be helpful as biomarkers to monitor
the progression of the disease and the impact of interven-
tional modalities aimed at halting eventual manifestation of
end-stage renal disease in diabetic patients.
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Introduction
Nephropathy is a microvascular complication of both type
1 and type 2 diabetes mellitus [1]. It is the leading cause of
end-stage renal disease (ESRD), and associated morbidity
and mortality, worldwide [2–4]. The course of diabetic
nephropathy remains unpredictable and the pathogenesis
of progression is not completely understood. A number of
risk factors have been suggested in the pathogenesis of
diabetic nephropathy including low birth weight, endo-
thelial dysfunction, smoking, renin-angiotensin system
stimulation, obesity, hyperglycemia and hypertension
(Fig. 1) [5–7]. The development of diabetic nephropathy
is a gradual process which mainly starts with progression
from normal albuminuria to microalbuminuria [urinary
albumin excretion (UAE) 30–300 mg/24 hours] for 5–
10 years [1, 8, 9]. Thus, microalbuminuria could be a
predictive marker for development of overt diabetic
nephropathy in the uncontrolled diabetic patient. None-
theless, with progression of the disease, blood pressure
increases associated with marked albuminuria (UAE>
300 mg/day) and a relentless decline in glomerular fil-
tration rate (GFR) [8, 9].
Hyperglycemia is a well-recognized causal factor for
development of diabetic microvascular complications in-
cluding nephropathy [10–12]. Accordingly, it is suggested
that hyperglycemia results in increased generation of
superoxide from a number of sources including the
mitochondria, the NADPH oxidase and the uncoupled
nitric oxide synthase (NOS) [13–19]. Superoxide exerts a
diverse array of effects that are considered detrimental to
the cell. For example, superoxide could scavenge nitric
oxide leading to the generation of peroxynitrite [20, 21].
This will have the dual effects of removing/attenuating the
protective effects of nitric oxide on the vasculature and
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generation of peroxynitrite which could damage proteins
and DNA [16, 21]. However, increased generation of
superoxide and peroxynitrite also results in DNA damage
and subsequent activation of the poly-ADP ribose poly-
merase [22, 23]. In turn, activation of poly-ADP ribose
polymerase exerts a number of effects including poly-ADP
ribosylation of other proteins including glycerladehyde-3-
phosphate dehydrogenase. Subsequently, increased avail-
ability of glycolytic intermediates causes their diversion
into other pathways including the polyol pathway, hexos-
amine pathway, protein kinase C (PKC) pathway and the
advanced glycation end (AGE) products pathway which are
ultimately linked to manifestation of diabetic microvascular
and macrovascular complications [24–28]. For example,
activation of PKC pathway is linked to activation of a
myriad of downstream pathways. These include a) in-
creased nuclear factor-κB (NF-κB) activation and subse-
quent pro-inflammatory gene expression [28–30], b)
increased NADPH oxidase and subsequent reactive oxygen
species (ROS) generation [28, 31–33], c) increased plas-
minogen activator inhibitor-1 (PAI-1)-induced reduction in
fibrinolysis and consequent vascular occlusion [28, 34, 35],
d) increased formation of vascular endothelial growth factor
(VEGF) thereby resulting in vascular permeability changes
and angiogenesis [28, 36, 37] and e) upregulation of
transforming growth factor-β (TGF-β), collagen and
fibronectin thereby promoting capillary occlusion and the
increase in extracellular matrix deposition [28, 38–40].
Clearly, the pathogenic mechanisms of hyperglycemia-
induced diabetic complications are complex and have been
the focus of previous reviews [24, 28]. However, as alluded
to earlier, one consequence of hyperglycemia-induced ROS
generation is activation of pro-inflammatory cascades
which, in turn, increase transcription of genes encoding
cytokines-chemokines, growth factors and extracellular
matrix proteins (Fig. 2) [41, 42]. Thus, this communication
will focus on the emerging role of inflammatory cytokines-
chemokines in relation to diabetic nephropathy. Given the
devastating consequences of diabetic renal disease, early
detection through identification of predictive biomarkers
could potentially lead to prevention of disease progression,

























Fig. 2 Schematic diagram showing the proposed relationship between
hyperglycemia, oxidative stress and inflammatory cytokines produc-
tion in the pathogenesis and progression of diabetic nephropathy.
ROS: reactive oxygen species; TNF-α: tumor necrosis factor-α;
NFκB: nuclear transcription factor-κ; MCP-1: monocyte chemo-
attractant protein-1; CAMs: cellular adhesion molecules; NO: nitric
oxide; TGF-β: transforming growth factor-β; CTGF: connective
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Fig. 1 A number of risk factors contribute to eventual manifestation
of insulin resistance/hyperglycemia. In turn, hyperglycemia results in
a myriad of metabolic and hemodynamic abnormalities that are
intimately associated with microvascular complication of diabetes
including nephropathy
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Inflammatory cytokines-chemokines and diabetic
nephropathy
Cytokines are redundant secreted proteins that exert a myriad
of effects including regulation and determination of the nature
of immune responses, immune cell trafficking and cellular
arrangements in immune organs [43]. Cytokines are produced
de novo following an immune stimulus; in turn, they regulate
proliferation of immune cells and their differentiation [43].
These include interleukin (IL)-1 (which activates T cells), IL-
2 (which stimulates proliferation of antigen-activated T and
B cells), IL-4, 5 and 6 (which stimulate proliferation and
differentiation of B-cells) as well as IL-3 and IL-7 (which
stimulate hematopoiesis), among others [44, 45].
Chemokines (chemotactic cytokines), also small secreted
proteins (7–10 kDa), play crucial roles in many pathological
processes including infection, allergic reaction, autoimmune
disease and inflammation [46, 47]. A distinguishing feature
of chemokines is the fact that they are the only members of
the cytokine family that act on the superfamily of G-protein
coupled serpentine receptors [46]. Once released, chemo-
kines interact with specific cell surface receptors (e.g., CC,
C, CXC and CX3C chemokine receptor subfamilies) of their
target cells [48]. Consequently, there is recruitment and
activation of leukocytes in preparation for mounting an
immune response and initiation of wound healing [49].
Constitutive production of chemokines v is believed to
regulate basal leukocytes trafficking. On the other hand, the
induction of chemokines during inflammation (e.g., in
response to early-response cytokines such as IL-1 and tumor
necrosis factor) is crucial for recruitment of leukocytes to
loci of immune reaction, a process regulated by mitogen-
activated protein kinases [50, 51]. A noted feature of the
process is the observation that the same stimulus can elicit
production of multiple chemokines form the same cell
thereby augmenting the inflammatory response. On the other
hand, hemostatic chemokines are involved in adaptive
immune responses such as lymphocyte trafficking, antigen
sampling in secondary lymphoid tissues and immune
surveillance [52].
Increasing evidence points to critical roles of pro-
inflammatory cytokines in pathogenesis of diabetic ne-
phropathy. For example, IL-1 is believed to increase
vascular permeability and proliferation of mesangial cells
and matrix deposition [4, 53]. On the other hand, IL-6
reportedly upregulates mesangial cell proliferation,
increases fibronectin expression and affects extracellular
matrix dynamics of mesangial cells and podocytes along
with increased expression of adhesion molecules on
endothelial cells and vascular smooth muscle cells [4, 54,
55]. Still other cytokines, such as tumor necrosis factor-α
(TNF-α), impair balance among vasodilator and vasocon-
striction mediators, upregulate production of ROS thereby
contributing to alterations in glomerular capillary perme-
ability barrier [4, 56]. Collectively, these effects are
believed to contribute to the functional alterations associ-
ated with diabetic nephropathy such as albuminuria and
dysregulation of sodium homeostasis.
Importantly, chemokine-induced inflammatory cell re-
cruitment into renal tissue is a critical feature of various
forms of renal disease including diabetic nephropathy. For
example, during early phase of diabetic nephropathy,
monocyte chemoattractant protein-1 (MCP-1) induces mac-
rophage recruitment and accumulation; this has been
reported both for experimental models of diabetes and
diabetic patients [57–59]. Chemokines also increase expres-
sion of intercellular and vascular cellular adhesion molecules
(ICAM-1, VCAM-1) and E-selectin leading to recruitment of
more monocytes and macrophages to site of inflammation
[60]. In fact, chemokines-induced proinflammatory gene
activation in diabetes leads to further production of cytokines
such as TNF, interleukins, and interferon-γ thereby establish-
ing a self-perpetuating cascade [61, 62]. The contributing
factors that stimulate expression of these genes are compo-
nents of the diabetic milieu including ROS, oxidized lipids,
reduced nitric oxide (NO), increased angiotensin II, free fatty
acids (FFA) and AGE products [4, 63]. Both endothelial cells
and macrophages contribute to altered vascular reactivity and
coagulation through increased expression of plasminogen
activator-1 (PAI-1) and tissue factor as well as through
platelet activation and increased generation of coagulation
factors such as fibrinogen and factor VIII [64]. Importantly, a
frequent accompanying feature of patients with type 2
diabetes is overweight/obesity and adipose tissue is known
to contribute importantly to the inflammatory process in
these individuals in both vascular and nonvascular tissues
[64]. Pro-inflammatory and procoagulant mediators re-
leased by adipose cells in obese subjects exert both local
and systemic effects on vascular metabolism and function
[65]. The adipose tissue of obese subjects contains acti-
vated macrophages that together with adipocytes produce
inflammatory mediators such as MCP-1, macrophage
inhibitory factor (MIF), TNF-α, and IL-6 as well as
vasoactive substances such as angiotensinogen and endo-
thelin [65–67].
The following describes the most relevant inflammatory
markers that are currently used or are under investigation as
predictive/diagnostic markers for diabetic nephropathy.
C-reactive protein (CRP)
CRP is an acute phase protein produced by liver cells in
response to various inflammatory stimuli; it is found in the
blood [4]. CRP is a member of the pentraxin family of
oligomeric proteins which is believed to play a fundamental
role in natural host defense and innate immunity [4, 68]. As
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a member of the class of acute-phase reactants, plasma
CRP level rises dramatically during acute inflammatory
processes [69, 70]. This is primarily due to the rise in the
serum concentration of macrophage-derived IL-6, the most
important stimulator of CRP production. Thus, CRP is a
very sensitive predictor of inflammation and it has been
associated with various inflammatory diseases such as
atherosclerosis, diabetes and myocardial infarction [4, 71].
Immunoregulatory functions of CRP include enhancement of
leukocyte reactivity, complement fixation, modulation of
platelet activation and clearance of cellular debris from sites
of active inflammation. It is well known that serum CRP
levels could serve as a sensitive circulating marker of
inflammation as CRP is independently associated with an
increased risk of cardiovascular diseases and diabetes
mellitus [72, 73]. In addition, experimental and clinical
studies suggest that CRP and IL-6 are sensitive physiological
markers of subclinical systemic inflammation which are
associated with insulin resistance and hyperglycemia [74].
Further, CRP level increases at early stages of diabetic
nephropathy and is independently associated with bio-
markers of glomerular and tubulointerestitial damage (e.g.,
urinary albumin excretion and urinary N-acetyl-β-glucosa-
minidase) [75–77]. Collectively, these observations suggest
that assessment of serum CRP may serve as a useful
predictive marker for detection and progression of diabetic
nephropathy (Table 1).
Tumor necrosis factor-alpha (TNF-α)
Monocytes and macrophages are key inflammatory cells
and components of the innate immunity [78]. Infiltration of
monocytes into renal tissue increases the release of
inflammatory mediators, including TNF-α which is a
pleiotropic cytokine, produced mainly in macrophages,
involved in systemic inflammation [78]. It is well estab-
lished that TNF-α plays a significant pathophysiological
role in different experimental models of renal diseases such
as lupus nephritis, crescentic glomerulonephritis, and the
remnant kidney model of nephropathy [79–81]. In diabetic
nephropathy, renal expression of TNF-α is increased
compared to kidneys of non-diabetic animals [82]. Macro-
phages from obese db/db mice display enhanced expression
of TNF-α. Glomerular and tubulointerestitial TNF-α gene
expression is also increased in diabetic rats [77, 83].
Exposure of tubular epithelial cells to TNF-α increased
the synthesis and secretion of lymphocyte chemoattractant
factors as well as the cell surface expression of intercellular
adhesion molecule-1 which has been implicated in the
development of renal injury in diabetes [84]. It is important
to note that TNF-α may not only be produced in the
diabetic kidney by infiltrating macrophages but also
intrinsically by renal cells such as endothelial, mesangial,
glomerular and tubular epithelial cells [76, 77, 83].
Additionally, the cytotoxic effects of TNF-α can directly
induce damage to glomerular, mesangial and epithelial cells
[56, 77]. TNF-α also promotes the local generation of
superoxide, which affects the barrier function of the
glomerular capillary wall resulting in enhanced albumin
permeability, independently of diabetic homodynamic
effects and inflammatory cytokines activation [56]. TNF-α
has stimulatory effects on sodium uptake by proximal
tubule cells contributing to sodium retention and renal
hypertrophy [85]. In experimental models of diabetic
Table 1 Role of several inflammatory cytokines in the pathogenesis of diabetic nephropathy and their potential predictive roles
Cytokine Role in Diabetic Nephropathy Possible prognostic Value
CRP An acute phase reactant that plays a fundamental role in
natural host defense and innate immunity during renal injury
Plasma CRP could be used as an indicator of early stages
of diabetic nephropathy
TNF-α Is involved in systemic inflammation via increasing the
formation of lymphocyte chemoattractant factors and cell
surface expression of intercellular adhesion molecule-1
which has been implicated in the development of diabetic
nephropathy
Urinary TNF-α levels could be used as a marker for the
development and progression of diabetic nephropathy
MCP-1 Mediates macrophage infiltration and accumulation in diabetic
nephropathy
Urinary MCP-1 levels is an important marker to detect the
progression of later stages of diabetic nephropathy
ICAM-1 Promotes leukocyte adhesion and is involved in renal
infiltration of macrophages in diabetic nephropathy
Urinary ICAM-1 could be used as an early marker for
monitoring the progression of diabetic nephropathy
TGF-β TGF-β plays an important role in the development of
glomerulosclerosis and interstitial fibrosis in diabetes via
enhancing glomerular extracellular matrix formation.
Urinary TGF-β could be used as an early marker for the
progression of diabetic nephropathy
CCN2 CCN2 is the key factor in stimulating connective tissue cell
proliferation, extracellular matrix production, and other
profibrotic properties of TGF-β during diabetes
1-Urinary CCN2 levels could be used as a marker of early
stage of diabetic nephropathy
2-Plasma CCN2 levels could be used as a marker for the
late stage of diabetic nephropathy
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nephropathy, renal TNF-α gene expression was also
increased in diabetic rats, with a significant correlation
between renal TNF-α expression and urinary TNF-α level
[83, 86]. The increase in renal TNF-α production in
diabetes appears to be related to hyperglycemia and
formation of AGE products [78]. diabetic patients had
approximately 3-fold higher serum TNF-α than non-
diabetic individuals; however, serum TNF-α concentration
was increased only in diabetic patients with micro- or
macro-albuminuria as well as in subjects with overt
nephropathy and renal insufficiency suggesting a signifi-
cant relationship between serum TNF-α and urinary
albumin excretion [77]. Diabetic patients with micro- or
macro-albuminuria had also elevated TNF-α expression
and urinary concentrations of TNF-α [83, 86]. Urinary
concentration of TNF-α may represent the local production
of this cytokine within the kidney as experimental studies
have demonstrated a direct and independent association
between renal TNF-α expression and urinary TNF-α
excretion with the severity of renal injury [87]. The
elevation in urinary TNF-α concentration in diabetic
patients with increased urinary albumin excretion was
further exacerbated as diabetic nephropathy progressed
[77]. Importantly, urinary TNF-α is significant and inde-
pendently related to clinical markers of both glomerular and
tubulointerestitial injury [77]. Thus, assessment of urinary
TNF-α levels could be used as a predictive marker for the
development and progression of renal injury in diabetic
nephropathy (Table 1).
Intercellular adhesion molecules-1 (ICAM-1)
ICAM-1 is a cell-surface protein with five immunoglobulin-
like domains [3]. Its production is induced by inflammatory
cytokines such as TNF-α, interleukin-1, and interferon-γ
[88]. Activation of PKC and shear stress in diabetes also
induce ICAM-1 [89, 90]. ICAM-1 expression on the
vascular endothelium and its binding to β2 leukocyte
integrins promotes leukocyte adhesion to the endothelium
[3]. Clinically, ICAM-1 expression is upregulated in renal
diseases such as human glomerulonephritis and in experi-
mental animal models of renal diseases such as glomerulo-
nephritis, renal ablation and ischemia/reperfusion injury
[91–94]. Renal ICAM-1 expression is increased during
diabetic nephropathy [95, 96]. For example, studies demon-
strated that macrophage infiltration and expression of adhesion
molecules including ICAM-1 and selectins increase in the
kidneys of patients with diabetic nephropathy, streptozotocin
(STZ)-induced diabetic rats, and in type 2 diabetes [96–98].
Blocking ICAM-1 signaling, with anti–ICAM-1 antibody,
prevented leukocyte influx into the glomeruli and reduced
renal injury in diabetes [99]. Glomerular infiltration of
macrophages and renal and glomerular hypertrophy in-
creased in ICAM-1+/+ diabetic mice and these changes
were accompanied with overproduction of TGF-β, accumu-
lation of glomerular type IV collagen, and albuminuria [3].
ICAM-1−/− diabetic mice showed a decrease in glomerular
macrophage infiltration and hypertrophy and reduced glo-
merular TGF-β and type IV collagen when compared with
ICAM-1+/+ diabetic mice [3]. Infiltration of CD4+ cells was
decreased in the glomeruli of diabetic ICAM-1-deficient db/
db mice compared with ICAM-1-intact db/db mice suggest-
ing that ICAM-1 is critically involved in renal infiltration of
macrophages in diabetic nephropathy [100]. Clinically, it has
been shown that patients with both type 1 and type 2 diabetes
mellitus and diabetic nephropathy have elevated concentra-
tions of plasma ICAM-1 compared with subjects without
renal injury indicating that assessment of plasma ICAM-1
levels can be used as a predictor of the development of renal
damage [101, 102]. Recent studies also showed that renal
ICAM-1 levels increased in diabetic patients and in
experimental models of diabetic nephropathy [103, 104].
These findings suggest that early assessment of plasma and
urinary ICAM-1 levels could be a useful marker for
diagnosis of diabetic nephropathy and preventing disease
progression (Table 1). Importantly, modulation of ICAM-1
activity may be a new venue for treating diabetic nephrop-
athy especially with the current trials developing ICAM-
1antagonists [105].
Monocyte chemoattractant protein-1 (MCP-1)
Chemokine (C-C motif) ligand 2 (CCL2) is a small
cytokine belonging to the CC chemokine family that is
also known as MCP-1 [106]. MCP-1 mediates macrophage
migration and recruits monocytes, memory T cells, and
dendritic cells to sites of tissue injury and infection [106,
107]. It is a monomeric polypeptide, with a molecular
weight of approximately 13 kDa [108]. As with many other
CC chemokines, CCL2 is located on chromosome 17 in
humans [108]. The cell surface receptors that bind CCL2
are chemokine receptor 2 and 4 (CCR2 and CCR4) [109].
The role of MCP-1 in the pathogenesis of diabetic renal
complications is clearly established. For example, high
concentrations of glucose and AGE products stimulate
MCP-1 production from cultured mesangial cells, podo-
cytes, and renal tubular epithelial cells [110–112] in vitro.
Increased glomerular macrophages infiltration was detected
before deposition of extracellular matrix component [113]
and MCP-1 was upregulated and has been shown to
mediate macrophage infiltration and accumulation during
the development of early diabetic nephropathy [7, 114]. In
addition, increased amounts of MCP-1 were detected in
renal biopsies and urine of patients with diabetic nephrop-
athy [58, 115, 116]. MCP-1 knockout mice have recently
been shown to be protected from streptozotocin (STZ)
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induced diabetic nephropathy and glomerular and tubuloin-
terestitial injury were abrogated in these mice [114].
Blockade of the MCP-1/CCR2 also reduced glomeruloscle-
rosis in STZ-induced diabetic mice [117]. These data
suggest that MCP-1 plays a crucial role in the progression
of diabetic nephropathy and inhibition of MCP-1 signaling
could be an important therapeutic goal in the treatment of
diabetic nephropathy.
Urinary MCP-1 was elevated in patients with diabetic
nephropathy, but with different patterns and implications
for progression of renal disease [7]. Elevated urinary MCP-
1 levels in diabetic patients with macroalbuminuria were
prognostic for deterioration in kidney function [7]. It was
found that urinary MCP-1 levels were better correlated with
the rate of deterioration of glomerular filtration rate (GFR)
than urinary protein/creatinine ratio suggesting that urinary
MCP-1 levels could provide a better prognostic tool in the
latter stage of diabetic nephropathy where patients have
symptoms of macroalbuminuria and worsening of GFR [7]
(Table 1). As indicated earlier, hypertension and poor
glycemic control are established factors in the progression
of diabetic nephropathy. However, neither HbA1c nor
blood pressure assessment showed a significant correlation
with urinary MCP-1 levels in patients with diabetic
nephropathy [7]. Therefore, measurement of urinary MCP-
1 levels could provide more accurate prognostic informa-
tion for the progression of diabetic nephropathy than blood
pressure and glycemic control assessment.
Transforming growth factor-β (TGF-β)
Glomerular hypertrophy is a characteristic feature of
diabetic nephropathy [118]. Recent evidence suggests that
pro-fibrotic growth factors are involved in the pathogenesis
of diabetic glomerular hypertrophy; these include increased
mesangial matrix that is mainly composed of type IV
collagen (Fig. 3) [118, 119]. This may relate to the fact that
diabetes mellitus upregulates TGF-β expression and sig-
naling, leading to increased collagen formation [120]. TGF-
β, a prosclerotic cytokine, is a member of the transforming
growth factor superfamily that controls proliferation and
cellular differentiation; three isozymes have been identified
and designated as TGF-β1, TGF-β2 and TGF-β3. Several
experimental and clinical studies demonstrate a major role
for TGF-β in development of glomerulosclerosis and
interstitial fibrosis in diabetes [121] as TGF-β plays a
central role in the enhancement of glomerular extracellular
matrix production in diabetic nephropathy [120–122]. This
is evident from studies indicating that TGF-β expression
and activity increases in glomerular mesangial cells and
proximal tubule cells during diabetes [123–125]. TGF-β
mRNA also increased in mesangial cells, podocytes and
tubular epithelial cells in diabetic nephropathy and was
further increased with the disease progression especially in
the glomeruli [121]. TGF-β is also involved in interstitial
fibrosis, another important histopathological change that
correlates with diabetic renal dysfunction [42, 126]. Thus,
as would be expected, inhibition of TGF-β prevented
glomerular enlargement and reduced fibrosis in experimen-
tal models of diabetic nephropathy [127, 128]. The
observation that urinary TGF-β excretion is elevated in
diabetic patients with micro- and macroalbuminuria, it
suggests a role for TGF-β in the development of diabetic
nephropathy [129, 130]. Thus assessment of urinary TGF-β
levels could serve as a predictive marker for early detection
and monitoring of the progression of diabetic nephropathy
(Table 1).
Connective tissue growth factor (CTGF)
CCN2, formerly named connective tissue growth factor
(CTGF), is now known to be a major downstream effector
of TGF-β signaling [131]. CCN2 is a 36- to 38-kDa protein
that was first identified in conditioned media of endothelial
cells as a polypeptide containing chemotactic activity
towards fibroblasts [132]. CCN2 is a crucial factor in
extracellular matrix production and other profibrotic activ-
ity mediated by TGF-β [132, 133]. It also plays an
important role in angiogenesis, cell adhesion, migration,
proliferation and differentiation [134]. Recently, CCN2 has
been shown to play an important role in the pathogenesis of
diabetic nephropathy [132]. High concentrations of glucose
and AGE products stimulated the production of both TGF-
β and CCN2 in mesangial cell cultures [135, 136]. CCN2 is
involved in diabetes-induced pathophysiological changes
such as extracellular matrix synthesis, cell migration, and
epithelial-to-mesenchymal transition [137, 138]. Further-
more, upregulation of CCN2 has also been demonstrated in
human and experimental models of diabetic nephropathy
[139–141]. Inhibition of CCN2 signaling preserved the
structure and function of the kidney in diabetic mice [142].
Because CCN2 is a secreted protein that can be detected
in biological fluids, recent studies suggest that urinary and
plasma CCN2 could serve as a predictive marker for
diabetic nephropathy. This hypothesis was supported by
the findings that both urinary CCN2 excretion and plasma
CCN2 levels are elevated in patients with diabetic nephrop-
athy [143, 144]. Although healthy individuals excrete low
levels of urinary CCN2, patients with diabetic nephropathy
and experimental animal models of diabetic nephropathy
exhibit significant CCN2 excretion [143, 145, 146].
Interestingly, urinary CCN2 levels were highest at the early
stage of diabetic nephropathy when patients were micro-
albuminuric and prospective follow up showed that raised
urinary CCN2 predicted worsening of microalbuminuria
[7]. In the streptozotocin-induced type 1 diabetes, urinary
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CCN2 excretion was elevated as early as 2 weeks following
the development of diabetes, peaked during the early
progression of diabetic nephropathy, and then decreased
as animals became proteinuric [145]. The early increase in
the urinary CCN2 in diabetic nephropathy supports the idea
that renal fibrosis starts early in the pathogenesis of diabetic
nephropathy, and that CCN2 is an important triggering
factor in this process [7].
Plasma CCN2 was also evaluated as a possible marker
for diabetic nephropathy and was found to be higher in
patients with diabetic nephropathy than in patients with
normoalbuminuria [132]. Plasma CCN2 level correlated
with rate of decline in GFR and was an independent
predictor of both ESRD and mortality in patients with type
1 diabetic nephropathy [132]. These data suggest that
plasma CCN2 is associated with decline in renal function in
type 1 diabetic patients with severe proteinuria than in those
with mild proteinuria and assessment of plasma CCN2 has
unique potential as a prognostic biomarker of renal function
decline, especially in diabetic patients with severe protein-
uria. Thus, assessment of plasma CCN2 levels could be
used to improve prediction of ESRD and mortality in
patients with type 1 diabetic nephropathy. The unique
predictive value of plasma CCN2 in the progression of
diabetic nephropathy, particularly in patients with severe
proteinuria, suggests that CCN2 could also be used as a
biomarker not only in diabetic patients who are likely to
develop clinical nephropathy, but also in those who will
exhibit rapid disease progression despite receiving appro-
priate treatment (Table 1).
Inflammatory cytokines; lessons from a diabetic animal
model
The obese Zucker rat (OZR) has an autosomal recessive
mutation of the fa gene encoding the leptin receptor [147,
148]. As a result, it manifests marked obesity which
becomes increasingly prominent, starting at about 6 weeks
of age, compared to their lean counterparts [148]. As shown
in Fig. 4, both fasting plasma glucose and insulin levels are
(significantly) higher in (6-month-old) OZR than lean
Zucker rats (LZR) suggestive of marked insulin resistance
of OZR; this is reflected from the calculated homeostatic
























Fig. 4 Bar graphs show fasting plasma glucose and insulin levels as
well as the homeostatic model assessment (HOMA) insulin resistance
index of (6-month-old) OZR, expressed as percent of values of LZR.
Also shown are hematoxylin-eosin stained sections of pancreas from
LZR and OZR rats (insets, 100×)
100 µM
Sham Rats STZ type1 Diabetic RatsFig. 3 shows immuno-
histochemical assessment of
collagen IV deposition in the
kidney section from
streptozotocin-induced type 1
diabetic rats and sham control
rat. Collagen IV deposition
(dark brown) increased in the
kidney section from diabetic vs.
sham control rat. Images are
shown at 200×
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based on fasting plasma glucose and insulin levels, which is
(significantly) higher for the OZR than LZR [148].
The marked compensatory hyperinsulinemia of OZR is
associated with prominent structural changes of the endo-
crine pancreas. Microscopic examination of the pancreas
from OZR reveals markedly enlarged hyperplastic islets of
Langerhans exhibiting benign cellular proliferation which
results in markedly irregular and jagged peripheral outline
compared to those of the LZR which show sharply
demarcated, small islets of Langerhans (Fig. 4). We have
a; 400x b; 400x
d; 200xc; 200x
Fig. 5 Oil-Red-O stained kid-
ney tissue from (6-month-old)
OZR show more numerous lipid
droplets compared to age-
matched LZR (panels a and b;
400×). Also shown are immu-
nostaining for CD 68 positive
cells (arrows) in kidney tissue
from experimental groups (pan-
els c and d; 200×)





































Fig. 6 Bar graphs show urinary excretions of albumin and monocyte
chemoattractant protein-1 (MCP-1) expressed as the percent of the
LZR group (panel A). Panel B shows that renal tissue from (6-month-
old) OZR displayed higher level of intercellular adhesion molecule-1
(ICAM-1) compared to age-matched LZR. Also shown are represen-
tative blots for ICAM-1 and β-actin (i.e., loading control). Data are
means±SEM of 7–9 animals/group. *p<0.05 compared to LZR
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shown that pancreatic islets of OZR display prominent
intercellular deposits of collagen fibers [148]. Collectively,
these histological findings are consistent with the interpre-
tation of islet hyperplasia with interstitial fibrosis of
pancreatic islets of OZR.
A noted physical feature of the OZR is marked
accumulation of fat within the abdominal cavity and
consequent effective encasement of the kidney with fat
deposits. Interestingly, local release of autocrine and para-
crine factors is believed to contribute importantly to the
pathogenesis of cardiac abnormalities in animals with
dietary fat-induced obesity [149]. Nonetheless, the rele-
vance of this mechanism for encapsulated organs, such as
the kidney, remains to be established. More importantly,
however, is the observation that OZR kidney displays
numerous lipid droplets compared to LZR kidney (Fig. 5,
panels a and b for LZR and OZR kidneys, respectively).
Ectopic lipid accumulation is suggested to contribute
importantly to organ dysfunction in obesity/type diabetes
(i.e., lipotoxicity) as adipocytes are sources of a myriad
factors including those promoting inflammatory changes
[150]. Indeed, renal tissue of OZR shows foci of interstitial
CD68 positive cells; whereas, examination of renal tissue
from LZR does not show CD68 positive cells (Fig. 5,
panels c and d for LZR and OZR kidneys, respectively).
Consistent with the notion of upregulation of inflammatory
processes associated with type 2 diabetes/ obesity, the OZR
group showed (significant) elevation in urinary excretion of
MCP-1 compared to LZR (Fig. 6a) [148]. Interestingly,
however, plasma CRP was similar between OZR and LZR
[0.62 ± 0.04 (n=8) vs. 0.58±0.07 (n=5) ng/ml, respective-
ly). As described earlier, plasma CRP is an index of early
changes in inflammatory status providing a likely explana-
tion for lack of a significant differential between LZR and
OZR at 6 months of age. Taken together, these observations
reinforce the notion that while plasma CRP may serve as a
useful predictive index at early stages of obesity/type 2
diabetes, urinary excretion of MCP-1 may be helpful in
monitoring the progression of renal disease and the efficacy
of interventional modalities. It is noteworthy that the kidney
of OZR displays increased levels of ICAM-1 compared to
that of LZR (Fig. 6b). This finding is consistent with our
recent demonstration that other indices of inflammation and
oxidative stress (i.e., tissue cyclooxygenase-2 and nitro-
tyrosine) are increased in kidneys of OZR than LZR [148].
As a functional correlate, Fig. 6a shows that OZR display
(significant) elevation in urinary albumin excretion [148].
Interestingly, however, blood pressure was similar between
OZR and LZR thereby suggestive of lack of a differential
contribution to genesis of proteinuria (although greater
sensitivity of OZR kidney to the same level of blood
pressure cannot be ruled out) [148]. Nonetheless, it is
important to note that multiple mechanisms contribute to
genesis of proteinuria including oxidative stress and
inflammatory chemokines and cytokines some of which
were significantly elevated in OZR than LZR as described
above [148].
Conclusion
Over the past decade, a close association between inflamma-
tion and diabetes has become increasingly clear. It is also
well-established that diabetic nephropathy is a devastating
complication of diabetes that often leads to ESRD. The
relationship between inflammatory cytokines-chemokines
levels and the development and progression of diabetic
nephropathy is very complex and requires further elucidation.
However, it is increasingly becoming clear that many
inflammatory cytokines-chemokines play significant roles in
this scenario, including adipokines, chemoattractant cyto-
kines, adhesion molecules, and pro-fibrotic cytokines. Be-
cause current treatment of diabetic nephropathy is still
suboptimal, early assessment of levels of some inflammatory
cytokines could potentially help with early diagnosis and
halting of disease progression to ESRD. Also, a better
understanding of the role of inflammatory cytokines-
chemokines in the progression of diabetic nephropathy should
facilitate the development of novel treatment(s) and improve-
ment of current therapeutic strategies. Nonetheless, given the
complex web of mechanisms that contribute to the genesis of
diabetic nephropathy, a pressing challenge is to identify
predictivemarkers for early detection of the disease. However,
it is unlikely that this important task can be relegated to a
single marker. Rather, in order to increase the power of
predictive strategies, multiple markers will be required to
increase the likelihood of early detection of the disease
process. Another important consideration is the need for to
identify minimally- or non-invasive sources for obtaining
these biomarkers such as those from the blood (or its
components) and/or urine. Clearly, temporal changes in the
levels of these biomarkers from such sources should reflect
changes occurring in target organs such as the kidney. To that
end, the OZR (and other relevant animals models) can serve as
valuable investigational tools to compare and contrast the
levels of molecular biomarkers in the organ of interest to those
of blood (or its components) and/or urine.
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